Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ricardo Restrepo‐Jaramillo"'
Autor:
Nick H. Kim, Kelly M. Chin, Vallerie V. McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Gwen MacDonald, Nicolas Martin, Daniel Rosenberg, Maria Solonets, Richard Channick
Publikováno v:
Pulmonary Therapy, Vol 10, Iss 1, Pp 85-107 (2024)
Abstract Introduction Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are usually excluded f
Externí odkaz:
https://doaj.org/article/d2d527f021da4bc98cd27bae7d4bdc4e
Autor:
Shelley Shapiro, Stacy Mandras, Ricardo Restrepo‐Jaramillo, Eric Shen, Meredith Broderick, Youlan Rao, Dasom Lee, Andrew C. Nelsen
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-7 (2021)
Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of patients are prescribed a higher dose than the maximum recommended dosage of nine breaths per t
Externí odkaz:
https://doaj.org/article/1be592dc6588428eabbfca9ed2a96c28
Autor:
Franck F. Rahaghi, Vijay P. Balasubramanian, Robert C. Bourge, Charles D. Burger, Murali M. Chakinala, Michael S. Eggert, Jean M. Elwing, Jeremy Feldman, Christopher King, James R. Klinger, Stephen C. Mathai, John Wesley McConnell, Harold I. Palevsky, Ricardo Restrepo‐Jaramillo, Zeenat Safdar, Jeffrey S. Sager, Namita Sood, Roxana Sulica, R. James White, Nicholas S. Hill
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies sugge
Externí odkaz:
https://doaj.org/article/9f5b66c79cd442eda20ab75c66cf4ff1
Autor:
Leslie A. Spikes, Abubakr A. Bajwa, Charles D. Burger, Sapna V. Desai, Michael S. Eggert, Karim A. El‐Kersh, Micah R. Fisher, Shilpa Johri, Joanna M. Joly, Jinesh Mehta, Harold I. Palevsky, Gautam V. Ramani, Ricardo Restrepo‐Jaramillo, Sandeep Sahay, Trushil G. Shah, Chunqin Deng, Melissa Miceli, Peter Smith, Shelley M. Shapiro
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebuliz
Externí odkaz:
https://doaj.org/article/54bf8d2f543344f38ef9f1658923dfa4
Autor:
Mauricio Orozco‐Levi, Jorge Cáneva, Caio Fernandes, Ricardo Restrepo‐Jaramillo, Nayeli Zayas, Rafael Conde, Mirta Diez, Carlos Jardim, Manuel C. Pacheco Gallego, Luciano Melatini, Héctor Valdéz, Tomás Pulido
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 1, Pp n/a-n/a (2022)
Abstract Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability. A group of experts
Externí odkaz:
https://doaj.org/article/0d708ba3098c416781382fb49ae78e18
Autor:
Debabrata Bandyopadhyay, Christopher Lai, Juan N. Pulido, Ricardo Restrepo-Jaramillo, Adriano R. Tonelli, Marc Humbert
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
Pulmonary hypertension (PH) confers a significant challenge in perioperative care. It is associated with substantial morbidity and mortality. A considerable amount of information about management of patients with PH has emerged over the past decade.
Externí odkaz:
https://doaj.org/article/4a5b263047c84c4dba47f990004c4b5c
Autor:
Diane L. Zwicke, Ricardo Restrepo-Jaramillo, Hassan Alnuaimat, Kathryn Gordon, Meredith Broderick, Lisa D. Edwards, Andrew Allmon, Peter J. Leary
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Oral treprostinil has recently been shown to delay disease progression in patients with pulmonary arterial hypertension in a long-term outcomes study. The potential advantages of an oral formulation have resulted in patients transitioning from inhale
Externí odkaz:
https://doaj.org/article/a964eba315d444f1852c279cc5f9d1c8
Autor:
Andrew Nelsen, Youlan Rao, Eric Shen, Dasom Lee, Stacy Mandras, Ricardo Restrepo-Jaramillo, Meredith Broderick, Shelley Shapiro
Publikováno v:
Pulmonary Circulation, Vol 11 (2021)
Pulmonary Circulation
Pulmonary Circulation
Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of patients are prescribed a higher dose than the maximum recommended dosage of nine breaths per t
Autor:
Chunqin Deng, Leigh Peterson, Kristan Rollins, Roblee P Allen, Rahul G. Argula, Heidi Bell, Aaron B. Waxman, Abubakr Bajwa, Steven D. Nathan, Pete Smith, Ashwin Ravichandran, Jeremy Feldman, Victor F. Tapson, Ricardo Restrepo-Jaramillo, Peter A. Engel, Thenappan Thenappan
Publikováno v:
New England Journal of Medicine. 384:325-334
No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear.We enrolled patients with interst
Autor:
Mauricio, Orozco-Levi, Jorge, Cáneva, Caio, Fernandes, Ricardo, Restrepo-Jaramillo, Nayeli, Zayas, Rafael, Conde, Mirta, Diez, Carlos, Jardim, Manuel C, Pacheco Gallego, Luciano, Melatini, Héctor, Valdéz, Tomás, Pulido
Publikováno v:
Repositorio Universidad de Santander
Universidad de Santander
instacron:Universidad de Santander
Universidad de Santander
instacron:Universidad de Santander
Digital
Treatment for pulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension in Latin America differs between countries, withregard to disease etiology, health insurance coverage, and drug availability. Agroup of expert
Treatment for pulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension in Latin America differs between countries, withregard to disease etiology, health insurance coverage, and drug availability. Agroup of expert
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6ac8031c8eb2ba18e0d971222729b83
https://repositorio.udes.edu.co/handle/001/7371
https://repositorio.udes.edu.co/handle/001/7371